Leukemia
News
LYN Kinase Affects Sensitivity to Gleevec® in Chronic Myeloid Leukemia
(07/01/2008)
A protein structure known as the LYN kinase appears to play an important role in the effectiveness of Gleevec® (imatinib mesylate) in chronic myeloid leukemia (CML) cancer cells. These results were recently published in the Journal of the National Cancer Institute.
Sprycel® Effective for Newly Diagnosed Chronic Myeloid Leukemia
(06/27/2008)
The targeted agent Sprycel® (dasatinib) is an effective treatment for patients newly diagnosed with chronic myeloid leukemia (CML). These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Flavopiridol Has Significant Activity in Relapsed Chronic Lymphocytic Leukemia
(06/26/2008)
Flavopiridol provides pronounced anticancer activity among patients with chronic lymphocytic leukemia (CLL) that has stopped responding to prior therapies. These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.
Tasigna® Effective for Patients with Newly Diagnosed Chronic Myeloid Leukemia
(06/25/2008)
The targeted agent Tasigna® (nilotinib) appears to be an effective treatment for patients with newly diagnosed chronic myeloid leukemia (CML). These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Treanda® Included in NCCN Guidelines for CLL and NHL
(05/05/2008)
The chemotherapy agent Treanda® (bendamustine) has been added to the treatment guidelines of the National Comprehensive Cancer Network (NCCN) as an accepted treatment option for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
More
Leukemia
Cancer News...